Clarithromycin in Preventing Bronchopulmonary Dysplasia in Ureaplasma urealyticum–Positive Preterm Infants
- 1 December 2011
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 128 (6), e1496-e1501
- https://doi.org/10.1542/peds.2011-1350
Abstract
OBJECTIVE: To evaluate the efficacy and safety of clarithromycin treatment in preventing bronchopulmonary dysplasia (BPD) in Ureaplasma urealyticum–positive preterm infants. PATIENTS AND METHODS: Nasopharyngeal swabs for U urealyticum culture were taken from infants with a birth weight between 750 and 1250 g in the first 3 postnatal days. Infants with a positive culture for U urealyticum were randomly assigned to 1 of 2 groups to receive either intravenous clarithromycin or placebo. All the patients were followed at least up to the 36th postmenstrual week. RESULTS: A total of 224 infants met the eligibility criteria of the study. Seventy-four (33%) infants had a positive culture for U urealyticum in the first 3 day cultures. The rate of BPD development was significantly higher in patients with U urealyticum positivity (15.9% vs 36.4%; P < .01). However, multivariate logistic regression analysis failed to reveal a significant association between the presence of U urealyticum and BPD development (odds ratio: 2.4 [95% confidence interval: 0.9–6.3]; P = .06). Clarithromycin treatment resulted in eradication of U urealyticum in 68.5% of the patients. The incidence of BPD was significantly lower in the clarithromycin group than in the placebo group (2.9% vs 36.4%; P < .001). Multivariate logistic regression analysis confirmed the independent preventive effect of clarithromycin for the development of BPD (odds ratio: 27.2 [95% confidence interval: 2.5–296.1]; P = .007). CONCLUSIONS: Clarithromycin treatment prevents development of BPD in preterm infants who are born at 750 to 1250 g and colonized with U urealyticum.Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and Safety of Oral Versus Intravenous Ibuprofen in Very Low Birth Weight Preterm Infants with Patent Ductus ArteriosusThe Journal of Pediatrics, 2011
- In-Vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 yearsClinical Microbiology & Infection, 2010
- Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double‐blind, placebo controlled trialPediatric Pulmonology, 2010
- Role of Ureaplasma Species in Neonatal Chronic Lung Disease: Epidemiologic and Experimental EvidencePediatric Research, 2009
- Maternal Genital Colonization with Ureaplasma urealyticum Promotes Preterm Delivery: Association of the Respiratory Colonization of Premature Infants with Chronic Lung Disease and Increased MortalityClinical Infectious Diseases, 2004
- Anti-inflammatory capabilities of macrolidesPharmacological Research, 2001
- Review of Macrolides and KetolidesDrugs, 2001
- Effects of Clarithromycin on Cultured Human Nasal Epithelial Cells and FibroblastsThe Laryngoscope, 2000
- Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: Results of a metaanalysisThe Journal of Pediatrics, 1995
- Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin againstMycoplasma pneumoniae, Mycoplasma hominis andUreaplasma urealyticumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990